Susquehanna International Group
MNPR icon

Susquehanna International Group’s Monopar Therapeutics MNPR Stock Holding History

Susquehanna International Group’s Portfolio MNPR Stock Details MNPR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$227K Buy
+4,137
New +$250K ﹤0.01% 11460
2025
Q4 		– Sell
-4,328
Closed -$353K – 13121
2025
Q3 		$353K Sell
4,328
-4,028
-48% -$180K ﹤0.01% 9739
2025
Q2 		$299K Buy
+8,356
New +$303K ﹤0.01% 10343
2024
Q1 		– Sell
-2,199
Closed -$3.74K – 12891
2023
Q4 		$3.74K Buy
2,199
+107
+5% +$217 ﹤0.01% 12143
2023
Q3 		$5.96K Buy
+2,092
New +$7.31K ﹤0.01% 11769
2022
Q4 		– Sell
-2,117
Closed -$16K – 13197
2022
Q3 		$16K Buy
+2,117
New +$20.1K ﹤0.01% 12672

Other funds holding MNPR

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
SVCM
Saturn V Capital Management Austin, Texas $552M AUM 551.78% 1-Year Est. Return
DM
Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Susquehanna International Group's MNPR Position: Q1 2026 in Review

Susquehanna International Group opened a new position in Monopar Therapeutics (MNPR) in Q1 2026: 4,137 shares worth $227K. The stake represents ﹤0.01% of the portfolio and ranks #11460 among its holdings. This is a return to the name: Susquehanna International Group previously reported a position in MNPR as recently as Q3 2025.

Susquehanna International Group first reported a position in MNPR in Q3 2022 and has held it in 6 quarters since. The position peaked at $353K in Q3 2025. 82 funds tracked by Wall St. Rank hold MNPR as of Q1 2026.

  • Susquehanna International Group held 4,137 shares of Monopar Therapeutics worth $227K as of Q1 2026.
  • Monopar Therapeutics was a new Susquehanna International Group position in Q1 2026.
  • Monopar Therapeutics made up ﹤0.01% of Susquehanna International Group's portfolio in Q1 2026, its #11460 holding.
  • Susquehanna International Group first reported a position in Monopar Therapeutics in Q3 2022 and has held it in 6 quarters since.
  • Susquehanna International Group's Monopar Therapeutics position peaked at $353K in Q3 2025.
  • 82 funds tracked by Wall St. Rank held Monopar Therapeutics as of Q1 2026.

Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.